MaxCyte Inc (MXCT) Ord USD0.01 (DI)
Share news, reports & tips
4 February 2021 09:41
(Sharecast News) - Cell engineering and life sciences company MaxCyte has announced a subscription to raise £40m, in a bid to strengthen its balance sheet.
20 January 2021 10:05
(Sharecast News) - Cell engineering specialist MaxCyte said on Wednesday that 2021 revenues were likely to grow at a faster than initially expected rate at the same time as it posted a solid set of earnings...
9 September 2020 09:35
(Sharecast News) - Life sciences company MaxCyte named Amanda Murphy as its chief financial officer on Wednesday, succeeding long-time CFO Ron Holtz.
21 February 2020 11:53
(Sharecast News) - Life sciences company MaxCyte announced the consolidation of its two lines of common stock into a single unrestricted line of common stock on Friday.
20 January 2020 10:58
(Sharecast News) - Clinical-stage life sciences company MaxCyte told investors on Monday that its board was "exceptionally positive" of the group's future following a stellar year.
4 December 2019 16:14
(Sharecast News) - Cell-based therapeutics and life sciences company MaxCyte has entered into a new development and commercialisation agreement with its existing partner KSQ Therapeutics, it announced on...
21 November 2019 16:40
(Sharecast News) - Cell-based therapies and life sciences company MaxCyte announced a clinical and commercial licence agreement with oncology company Vor Biopharma on Thursday, under which Vor would use...
17 July 2019 10:52
(Sharecast News) - Clinical-stage life sciences company Maxcyte continued to build upon its "substantial momentum" during the first half of its trading year, putting it firmly in line with...
26 May 2019 21:53
(Sharecast News) - In his 'Inside the City' column for The Sunday Times, Ben Woods looked at the effect of Donald Trump's posturing against Huawei on the chipmaking industry - particularly,...
8 May 2019 15:58
(Sharecast News) - Clinical-stage, cell-based therapies and life sciences company MaxCyte has initiated dosing for the second cohort of patients in its US phase 1 clinical trial with MCY-M11 - the lead,...
8 April 2019 08:34
(Sharecast News) - MaxCyte on Monday launched its ExPERT technology platform, a family of instruments that are the next generation of its complex cellular engineering technology.
12 November 2018 12:50
(Sharecast News) - Cell-based medicines and life sciences company MaxCyte confirmed on Monday that it has entered into a research agreement with Kite, a subsidiary of American biotechnology giant Gilead.
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.